What is Dr. Zubair Khalid's research focus?

Dr. Zubair Khalid specializes in molecular virology, mRNA vaccine development, and computational biology, with a focus on avian pathogens like IBDV and Avian Reovirus.

Where is Dr. Zubair Khalid currently working?

Dr. Zubair Khalid is a Postdoctoral Research Associate at the University of Maryland (UMD), specifically within the Department of Animal and Avian Sciences.

Canine Splenic Masses: Diagnosis and Surgical Management

Splenic masses in dogs present a common diagnostic and surgical challenge in veterinary practice. The differential diagnosis includes benign lesions such as hematoma and nodular hyperplasia, as well as malignant neoplasms, most notably hemangiosarcoma. This article provides an evidence-based framework for the diagnostic workup, surgical decision-making, and postoperative management of canine splenic masses, drawing on peer-reviewed literature and established veterinary guidelines.

At a Glance

Diagnostic Category	Common Lesions	Typical Presentation	Key Diagnostic Features	Prognostic Considerations
Benign	Hematoma, nodular hyperplasia	Often incidental finding, may present with acute collapse if ruptured	Well-defined margins on ultrasound, cytology shows benign spindle cells or lymphoid hyperplasia	Excellent post-splenectomy survival, recurrence unlikely
Malignant - Vascular	Hemangiosarcoma	Acute hemoperitoneum, weakness, pallor, abdominal distension	Irregular, heterogeneous mass, cytology shows malignant endothelial cells, high metastatic rate	Poor median survival (months), chemotherapy may extend survival
Malignant - Other	Histiocytic sarcoma, liposarcoma	Variable, may mimic hemangiosarcoma clinically	Cytology shows histiocytic or lipocytic differentiation, immunohistochemistry may be needed	Variable, histiocytic sarcoma carries poor prognosis, liposarcoma may have better outcome

Clinical Presentation and Initial Assessment

Signalment and History

Splenic masses occur across all dog breeds and ages, but certain patterns emerge. A study examining splenic mass diagnosis according to breed size found that breed size influences the likelihood of benign versus malignant lesions (Splenic mass diagnosis in dogs undergoing splenectomy according to breed size, The Veterinary record, 2019, PubMed). Medium to large breed dogs, particularly those over 10 years of age, present more frequently with malignant masses. German Shepherd Dogs, Golden Retrievers, and Labrador Retrievers appear overrepresented in hemangiosarcoma case series.

Common presenting complaints include:

Acute weakness or collapse
Abdominal distension
Pale mucous membranes
Anorexia or lethargy
Incidental finding on abdominal palpation or imaging

Physical Examination Findings

Perform a complete physical examination with attention to:

Mucous membrane color and capillary refill time
Heart rate and pulse quality
Abdominal palpation for cranial organomegaly or fluid wave
Rectal temperature
Thoracic auscultation for arrhythmias or murmurs

Dogs with acute hemoperitoneum may present with tachycardia, pale mucous membranes, weak femoral pulses, and a distended, fluid-filled abdomen. Those with chronic, non-ruptured masses may have no abnormalities on physical examination.

Emergency Stabilization

For dogs presenting with acute hemoperitoneum and hemodynamic instability:

Establish intravenous access with two large-bore catheters
Administer isotonic crystalloid fluids at shock rates (monitor for volume overload)
Consider colloid therapy or blood products if available
Perform abdominocentesis to confirm hemoperitoneum
Obtain baseline bloodwork including packed cell volume, total solids, coagulation profile, and blood type

The Merck Veterinary Manual provides guidance on emergency management of hemorrhagic shock in dogs (Merck Veterinary Manual, www.merckvetmanual.com).

Diagnostic Workup

Abdominal Ultrasound

Abdominal ultrasound is the primary imaging modality for characterizing splenic masses. Key sonographic features to assess include:

Mass size, shape, and echogenicity
Presence of cavitation, necrosis, or mineralization
Relationship to splenic capsule and vasculature
Evidence of rupture (perisplenic fluid, hemoperitoneum)
Evaluation of other abdominal organs for metastatic disease

A 2024 study found that ultrasonographic liver nodules in dogs with hemoperitoneum secondary to splenic tumor rupture are more often benign lesions (Ultrasonographic liver nodules are more often benign lesions in dogs with hemoperitoneum secondary to splenic tumor rupture, Journal of the American Veterinary Medical Association, 2024, PubMed). This finding has important implications for surgical decision-making, as the presence of liver nodules should not automatically preclude splenectomy.

Fine-Needle Aspiration and Cytology

Ultrasound-guided fine-needle aspiration of splenic masses can provide cytologic diagnosis. However, limitations exist:

Hemangiosarcoma may yield only blood or nondiagnostic samples
Hematoma and hemangiosarcoma can appear similar cytologically
Necrotic or cavitated areas may not yield diagnostic cells

When performing aspiration, target the solid, non-cavitated portions of the mass. Prepare multiple slides and submit for cytologic evaluation. If cytology is equivocal, consider core needle biopsy or proceed directly to surgical excision with histopathology.

Staging for Metastatic Disease

Before surgical intervention, stage the patient for metastatic disease:

Three-view thoracic radiographs for pulmonary metastases
Abdominal ultrasound for liver, lymph node, and omental metastases
Consider computed tomography for more sensitive detection of metastases

The American College of Veterinary Internal Medicine provides resources on diagnostic imaging and staging protocols for canine neoplasia (ACVIM, www.acvim.org).

Coagulation Assessment

Splenic masses can cause hemostatic abnormalities. A 2022 study evaluated pre-operative hemostatic status in dogs undergoing splenectomy for splenic masses (Pre-operative Hemostatic Status in Dogs Undergoing Splenectomy for Splenic Masses, Frontiers in veterinary science, 2022, PubMed). Coagulation testing should include:

Prothrombin time
Activated partial thromboplastin time
Platelet count
Buccal mucosal bleeding time if indicated

Dogs with hemangiosarcoma may have disseminated intravascular coagulation or thrombocytopenia. Correct coagulopathies before surgery when possible.

The Double Two-Thirds Rule

A systematic review evaluated the validity of the double two-thirds rule for diagnosing hemangiosarcoma in dogs with nontraumatic hemoperitoneum due to a ruptured splenic mass (Evaluation of the validity of the double two-thirds rule for diagnosing hemangiosarcoma in dogs with nontraumatic hemoperitoneum due to a ruptured splenic mass: a systematic review, Journal of the American Veterinary Medical Association, 2022, PubMed). This rule states that approximately two-thirds of splenic masses are malignant, and two-thirds of malignant splenic masses are hemangiosarcoma. The review found variable accuracy, emphasizing that histopathology remains the gold standard for diagnosis.

Surgical Management

Indications for Splenectomy

Splenectomy is indicated for:

Confirmed or suspected malignant splenic mass
Ruptured splenic mass with hemoperitoneum
Large benign masses causing clinical signs (pain, gastrointestinal obstruction)
Diagnostic biopsy when less invasive methods are inconclusive

Preoperative Preparation

Before surgery:

Cross-match and have blood products available
Administer broad-spectrum antibiotics (cefazolin or equivalent)
Place a urinary catheter for monitoring urine output
Prepare for potential massive transfusion
Have a cell salvage device available if possible

Surgical Technique

Open Splenectomy

The standard approach is through a ventral midline celiotomy. Key steps include:

Make an incision from xiphoid to pubis
Explore the abdomen for metastatic disease
Isolate the splenic pedicle and ligate the splenic artery and vein
Ligate short gastric vessels if necessary
Remove the spleen and submit for histopathology
Perform abdominal lavage and closure

Laparoscopic Splenectomy

Videolaparoscopic splenectomy with bipolar electrosurgery has been described for splenic masses (Videolaparoscopic splenectomy with bipolar electrosurgery in dog with splenic mass, Acta Scientiae Veterinariae, 2015, Elsevier). This approach offers:

Reduced postoperative pain
Faster recovery
Smaller incisions
Shorter hospital stay

However, laparoscopic splenectomy requires specialized equipment and training. It is contraindicated in hemodynamically unstable patients or those with suspected splenic rupture.

Intraoperative Decision-Making

During surgery, assess the following:

Presence of metastatic lesions in liver, lymph nodes, omentum, or peritoneum
Degree of splenic vascular involvement
Ability to achieve complete resection

If metastatic disease is identified, consider:

Biopsy of suspicious lesions
Lymph node extirpation
Partial hepatectomy if solitary liver metastasis is present
Abandoning surgery if widespread metastases are found

Biopsy of Other Organs

When liver nodules are present, obtain biopsy samples for histopathology. As noted earlier, liver nodules in dogs with hemoperitoneum secondary to splenic tumor rupture are more often benign (Ultrasonographic liver nodules are more often benign lesions in dogs with hemoperitoneum secondary to splenic tumor rupture, Journal of the American Veterinary Medical Association, 2024, PubMed). This finding supports proceeding with splenectomy even when liver nodules are present, as they may represent nodular hyperplasia instead of metastasis.

Histopathologic Diagnosis

Common Splenic Masses

Hemangiosarcoma

Hemangiosarcoma is the most common malignant splenic neoplasm in dogs. It arises from vascular endothelium and is highly metastatic. Histologically, it appears as irregular, blood-filled spaces lined by pleomorphic endothelial cells. Immunohistochemistry for factor VIII-related antigen or CD31 can confirm the diagnosis.

Hematoma

Splenic hematoma is a benign lesion consisting of organized blood clot within the splenic parenchyma. It may be difficult to distinguish from hemangiosarcoma grossly. Histopathology shows a well-demarcated mass of erythrocytes, fibrin, and hemosiderin-laden macrophages.

Nodular Hyperplasia

Nodular hyperplasia is a benign proliferation of splenic lymphoid and hematopoietic tissue. It is common in older dogs and often an incidental finding. Histologically, it appears as well-circumscribed nodules of hyperplastic white pulp.

Histiocytic Sarcoma

Canine hemophagocytic histiocytic sarcoma is a proliferative disorder of CD11d+ macrophages (Canine hemophagocytic histiocytic sarcoma: a proliferative disorder of CD11d+ macrophages, Veterinary pathology, 2006, PubMed). This aggressive neoplasm can involve the spleen and other organs. It carries a poor prognosis.

Liposarcoma

Splenic liposarcoma is a rare malignant mesenchymal tumor. A case series described 13 cases of splenic liposarcoma in dogs (Splenic liposarcoma in dogs: 13 cases (2002-2012), Journal of the American Veterinary Medical Association, 2015, PubMed). These tumors may have a better prognosis than hemangiosarcoma, but metastatic potential exists.

Histopathologic Evaluation

Submit the entire spleen for histopathologic examination. The pathologist should evaluate:

Tumor type and grade
Surgical margins
Vascular invasion
Mitotic index
Presence of necrosis or hemorrhage

Postoperative Care

Immediate Postoperative Period

Monitor the patient closely for:

Hemorrhage from the splenic pedicle
Cardiac arrhythmias (ventricular premature complexes are common after splenectomy)
Hypotension and hypoperfusion
Pain management

Administer:

Intravenous fluids at maintenance rates
Analgesics (opioids, nonsteroidal anti-inflammatory drugs if no contraindications)
Antibiotics for 24 hours postoperatively
Antiarrhythmics if indicated (lidocaine, sotalol)

Monitoring Parameters

Record the following every 4-6 hours for the first 24-48 hours:

Heart rate and rhythm
Respiratory rate and effort
Mucous membrane color and capillary refill time
Packed cell volume and total solids
Blood pressure
Urine output
Pain score

Discharge Criteria

Discharge the patient when:

Hemodynamically stable
Eating and drinking
Pain controlled with oral medications
No evidence of hemorrhage or arrhythmia
Owner understands postoperative care and monitoring

Long-Term Monitoring

For dogs with benign lesions, no further monitoring is required beyond routine wellness care. For dogs with malignant lesions, schedule:

Recheck examinations every 1-3 months
Thoracic radiographs every 2-3 months
Abdominal ultrasound every 2-3 months
Bloodwork including complete blood count and chemistry panel

Prognostic Factors

Benign Lesions

Dogs with splenic hematoma have an excellent prognosis following splenectomy. A study of 35 dogs with splenic hematoma reported favorable outcomes (Outcome and prognostic factors for dogs with a histological diagnosis of splenic hematoma following splenectomy: 35 cases (2001-2013), Canadian Veterinary Journal, 2016, Elsevier). Median survival time exceeds 2 years in most cases.

Malignant Lesions

Prognosis for hemangiosarcoma is poor, with median survival times of 2-3 months with surgery alone and 6-9 months with adjuvant chemotherapy. Negative prognostic factors include:

Rupture at presentation
Metastatic disease at diagnosis
High mitotic index
Vascular invasion
Large tumor size

Histiocytic sarcoma carries a similarly poor prognosis. Liposarcoma may have a more favorable outcome, but data are limited.

Common Failure Patterns

Diagnostic Errors

Misinterpreting hematoma as hemangiosarcoma on ultrasound
Relying solely on cytology without histopathology
Failing to stage for metastatic disease before surgery
Assuming liver nodules are metastatic without biopsy

Surgical Complications

Hemorrhage from the splenic pedicle
Cardiac arrhythmias (ventricular premature complexes, ventricular tachycardia)
Pancreatitis from pancreatic trauma during splenectomy
Gastric dilation-volvulus in predisposed breeds
Wound infection or dehiscence

Postoperative Management Failures

Inadequate pain control
Failure to monitor for arrhythmias
Delayed recognition of hemorrhage
Incomplete histopathologic evaluation
Lack of follow-up for malignant lesions

Limitations and Considerations

Diagnostic Limitations

Ultrasound cannot reliably distinguish benign from malignant masses
Fine-needle aspiration has limited sensitivity for hemangiosarcoma
Staging may miss micrometastatic disease
The double two-thirds rule is not universally accurate

Surgical Limitations

Laparoscopic splenectomy requires specialized equipment and training
Massive transfusion may be needed for ruptured masses
Complete resection may not be possible with extensive vascular involvement
Concurrent metastatic disease may preclude curative surgery

Prognostic Limitations

Histopathology is the gold standard but cannot predict individual outcomes
Chemotherapy protocols vary and response is unpredictable
Long-term survival data for rare tumor types are limited

Professional Escalation Criteria

Refer to a veterinary oncologist or surgical specialist when:

The mass is large or involves the splenic hilus
Metastatic disease is suspected or confirmed
The patient has concurrent coagulopathy
Laparoscopic splenectomy is desired
Adjuvant chemotherapy is being considered
The diagnosis is uncertain after initial workup

The American Animal Hospital Association provides resources for referral to board-certified specialists (AAHA, www.aaha.org).

Practical Decision Framework for Splenic Mass Management: The Three-Tier Risk Stratification Model

Managing canine splenic masses requires a structured approach that balances diagnostic certainty, surgical urgency, and owner expectations. A three-tier risk stratification model provides a practical framework for clinical decision-making based on available evidence and patient-specific factors. This model integrates preoperative findings, intraoperative assessment, and histopathologic confirmation to guide management at each stage of care.

Tier 1: Preoperative Risk Stratification

The first tier categorizes patients based on clinical presentation, imaging characteristics, and preliminary laboratory findings. This stratification guides the urgency of intervention and informs preoperative discussions with owners.

Low-Risk Category

Patients meeting all of the following criteria:

Incidental finding on abdominal palpation or imaging
No evidence of hemoperitoneum on ultrasound
Mass less than 5 cm in diameter
Well-defined, homogeneous echogenicity on ultrasound
Normal coagulation profile (prothrombin time, activated partial thromboplastin time, platelet count)
No evidence of metastatic disease on thoracic radiographs and abdominal ultrasound
Breed not predisposed to hemangiosarcoma (e.g., small breed dogs)

For low-risk patients, consider:

Elective scheduling of splenectomy with histopathology
Preoperative fine-needle aspiration for cytology (acknowledging limitations)
Owner education about the 30-40% probability of malignancy based on published data

Moderate-Risk Category

Patients meeting any of the following criteria:

Mass 5-10 cm in diameter
Heterogeneous echogenicity with cavitation or necrosis
Mild hemoperitoneum (small volume, patient hemodynamically stable)
Breed predisposition for hemangiosarcoma (German Shepherd Dog, Golden Retriever, Labrador Retriever)
Age over 10 years
Mild thrombocytopenia or prolonged coagulation times

For moderate-risk patients:

Schedule splenectomy within 24-48 hours
Cross-match and prepare blood products
Stage for metastatic disease before surgery
Discuss 50-70% probability of malignancy with owners

High-Risk Category

Patients meeting any of the following criteria:

Acute hemoperitoneum with hemodynamic instability
Mass greater than 10 cm in diameter
Evidence of rupture on ultrasound
Moderate to severe thrombocytopenia or coagulopathy
Suspicious metastatic lesions on staging
Previous history of splenic mass or hemangiosarcoma

For high-risk patients:

Emergency splenectomy after stabilization
Immediate cross-match and blood product availability
Cell salvage device if available
Discuss 70-90% probability of malignancy with owners
Prepare for potential intensive care unit admission postoperatively

Tier 2: Intraoperative Decision Algorithm

The second tier provides a structured approach to intraoperative findings and decisions. This algorithm helps surgeons respond to unexpected findings and make real-time decisions about the extent of surgery.

Step 1: Abdominal Exploration

Upon entering the abdomen, perform a systematic exploration:

Evaluate the splenic mass: size, location, vascular involvement, evidence of rupture
Inspect the liver: number, size, and appearance of nodules
Examine the mesenteric lymph nodes: enlargement, discoloration, texture
Assess the omentum and peritoneum for implants or discoloration
Evaluate the gastrointestinal tract for concurrent abnormalities

Document all findings in the medical record with specific measurements and descriptions.

Step 2: Splenic Pedicle Assessment

Determine the feasibility of complete resection:

Is the mass confined to the spleen with a definable pedicle?
Are the splenic artery and vein free of tumor invasion?
Is there adequate length for ligation proximal to the mass?

If the mass involves the splenic hilus or extends into the pancreatic tissue, consider:

Careful dissection to preserve pancreatic blood supply
Partial pancreatectomy if necessary
Consultation with a surgical specialist if available

Step 3: Liver Nodule Evaluation

When liver nodules are present, follow this protocol:

Count and measure all visible nodules
Note the color, texture, and distribution
Obtain wedge biopsy or core needle biopsy of at least one nodule
Submit separate samples for histopathology

A 2024 study found that ultrasonographic liver nodules in dogs with hemoperitoneum secondary to splenic tumor rupture are more often benign lesions (Ultrasonographic liver nodules are more often benign lesions in dogs with hemoperitoneum secondary to splenic tumor rupture, Journal of the American Veterinary Medical Association, 2024, PubMed). This finding supports proceeding with splenectomy even when liver nodules are present, as they may represent nodular hyperplasia instead of metastasis.

Step 4: Lymph Node Assessment

Evaluate and biopsy regional lymph nodes:

Splenic lymph node (located near the splenic hilus)
Hepatic lymph node
Mesenteric lymph nodes

Enlarged or discolored lymph nodes should be excised or biopsied for histopathology. Normal-appearing lymph nodes may still contain micrometastatic disease, particularly in hemangiosarcoma.

Step 5: Decision to Proceed or Abort

Consider aborting splenectomy only in the following circumstances:

Widespread peritoneal carcinomatosis
Extensive liver metastasis involving more than 50% of hepatic parenchyma
Uncontrollable hemorrhage from the splenic pedicle
Patient becomes hemodynamically unstable despite resuscitation

In most cases, splenectomy should proceed even with metastatic disease because:

Removal of the primary mass reduces the risk of fatal hemorrhage
Cytoreduction may improve response to adjuvant therapy
Histopathologic diagnosis guides treatment recommendations
Palliative benefit for patients with clinical signs

Tier 3: Postoperative Risk Stratification and Monitoring

The third tier uses histopathologic diagnosis to guide long-term monitoring and adjuvant therapy recommendations.

Benign Lesion Protocol

For dogs with histopathologic confirmation of:

Splenic hematoma
Nodular hyperplasia
Splenic infarction
Benign lymphoid hyperplasia

Recommended monitoring:

Routine wellness examinations every 6-12 months
No specific imaging or bloodwork required
Owner education about signs of recurrence (rare)
Return to normal activity within 2-4 weeks

A study of 35 dogs with splenic hematoma reported favorable outcomes following splenectomy (Outcome and prognostic factors for dogs with a histological diagnosis of splenic hematoma following splenectomy: 35 cases (2001-2013), Canadian Veterinary Journal, 2016, Elsevier). Median survival time exceeds 2 years in most cases.

Low-Grade Malignancy Protocol

For dogs with histopathologic confirmation of:

Low-grade hemangiosarcoma (low mitotic index, no vascular invasion)
Liposarcoma
Leiomyosarcoma
Fibrosarcoma

Recommended monitoring:

Physical examination every 2-3 months for the first year
Thoracic radiographs every 2-3 months
Abdominal ultrasound every 2-3 months
Complete blood count and chemistry panel every 2-3 months
Consider referral to veterinary oncologist for adjuvant therapy discussion

A case series described 13 cases of splenic liposarcoma in dogs (Splenic liposarcoma in dogs: 13 cases (2002-2012), Journal of the American Veterinary Medical Association, 2015, PubMed). These tumors may have a better prognosis than hemangiosarcoma, but metastatic potential exists.

High-Grade Malignancy Protocol

For dogs with histopathologic confirmation of:

High-grade hemangiosarcoma (high mitotic index, vascular invasion, rupture)
Histiocytic sarcoma
Undifferentiated sarcoma
Metastatic disease at presentation

Recommended monitoring:

Physical examination every 1-2 months
Thoracic radiographs every 1-2 months
Abdominal ultrasound every 1-2 months
Complete blood count, chemistry panel, and coagulation profile every 1-2 months
Immediate referral to veterinary oncologist
Consider adjuvant chemotherapy (doxorubicin-based protocols)
Discuss clinical trial options

Record System for Splenic Mass Cases

A standardized record system ensures consistent documentation and facilitates outcome tracking. Implement the following minimum data set for every splenic mass case:

Preoperative Record

Patient signalment (breed, age, sex, weight)
Presenting complaint and duration
Physical examination findings (mucous membrane color, heart rate, pulse quality, abdominal palpation)
Ultrasound findings (mass size, echogenicity, cavitation, rupture, hemoperitoneum volume)
Staging results (thoracic radiographs, abdominal ultrasound, any additional imaging)
Laboratory values (packed cell volume, total solids, platelet count, prothrombin time, activated partial thromboplastin time)
Risk stratification category (low, moderate, high)
Owner discussion summary (risks, prognosis, cost estimates)

Intraoperative Record

Abdominal exploration findings (liver, lymph nodes, omentum, peritoneum)
Splenic mass description (size, location, vascular involvement, rupture)
Surgical technique (open vs. laparoscopic, ligation method)
Estimated blood loss
Blood products administered
Biopsy sites and sample identification
Complications encountered
Surgeon name and credentials

Postoperative Record

Histopathologic diagnosis (tumor type, grade, margins, vascular invasion, mitotic index)
Complication monitoring (arrhythmias, hemorrhage, pancreatitis)
Pain scores and analgesic requirements
Discharge date and medications
Follow-up schedule
Owner instructions

Long-Term Follow-Up Record

Recheck examination findings
Imaging results (thoracic radiographs, abdominal ultrasound)
Laboratory values
Adjuvant therapy details (chemotherapy protocol, doses, adverse effects)
Survival time and cause of death
Quality of life assessment

Common Failure Patterns in Splenic Mass Management

Diagnostic Failures

Overreliance on ultrasound alone: Ultrasound cannot reliably distinguish benign from malignant masses. A systematic review evaluated the validity of the double two-thirds rule for diagnosing hemangiosarcoma in dogs with nontraumatic hemoperitoneum due to a ruptured splenic mass (Evaluation of the validity of the double two-thirds rule for diagnosing hemangiosarcoma in dogs with nontraumatic hemoperitoneum due to a ruptured splenic mass: a systematic review, Journal of the American Veterinary Medical Association, 2022, PubMed). The review found variable accuracy, emphasizing that histopathology remains the gold standard.
Inadequate staging: Failing to obtain thoracic radiographs or abdominal ultrasound before surgery may miss metastatic disease and lead to inappropriate surgical decisions.
Cytology misinterpretation: Fine-needle aspiration of splenic masses has limited sensitivity for hemangiosarcoma. Blood contamination or sampling from necrotic areas can yield nondiagnostic or misleading results.

Surgical Failures

Incomplete hemostasis: Inadequate ligation of the splenic artery and vein can lead to life-threatening postoperative hemorrhage. Use of vascular clips or stapling devices may reduce this risk.
Pancreatic trauma: The splenic vasculature runs in close proximity to the pancreas. Aggressive dissection can cause pancreatitis, which complicates recovery and prolongs hospitalization.
Missed concurrent lesions: Failure to thoroughly explore the abdomen may result in missed metastatic lesions or concurrent splenic pathology.

Postoperative Management Failures

Inadequate arrhythmia monitoring: Ventricular arrhythmias are common after splenectomy, particularly in dogs with hemangiosarcoma. Continuous electrocardiographic monitoring for the first 24-48 hours is recommended.
Delayed recognition of hemorrhage: Postoperative hemorrhage from the splenic pedicle can be subtle. Serial packed cell volume measurements and blood pressure monitoring are essential.
Incomplete histopathologic evaluation: Submitting only a portion of the spleen or failing to provide adequate clinical history to the pathologist can result in incomplete or inaccurate diagnosis.

Welfare and Safety Context

Splenic masses in dogs present significant welfare concerns, particularly when they rupture and cause acute hemoperitoneum. The World Organisation for Animal Health provides guidelines for animal health and welfare that apply to surgical management of companion animals (Animal Health and Welfare, World Organisation for Animal Health, www.woah.org). Key welfare considerations include:

Pain management: Dogs with splenic masses may experience chronic discomfort from mass effect or acute pain from rupture. Multimodal analgesia should be provided before, during, and after surgery.
Quality of life assessment: For dogs with malignant splenic masses, quality of life should be assessed regularly using validated tools. Owners should be counseled about expected outcomes and signs of deterioration.
Euthanasia considerations: When metastatic disease is extensive or the patient's quality of life is poor, euthanasia may be the most humane option. This decision should be made collaboratively with the owner and based on objective assessment.
Anesthetic safety: Dogs with hemoperitoneum and hemodynamic instability are at increased anesthetic risk. Preoperative stabilization, careful anesthetic monitoring, and availability of blood products are essential.

Professional Escalation Criteria

Refer to a veterinary oncologist or surgical specialist when:

The mass is large (greater than 10 cm) or involves the splenic hilus
Metastatic disease is suspected or confirmed on preoperative staging
The patient has concurrent coagulopathy that cannot be corrected
Laparoscopic splenectomy is desired but the surgeon lacks experience
Adjuvant chemotherapy is being considered for malignant lesions
The diagnosis is uncertain after initial workup and fine-needle aspiration
The patient has recurrent splenic masses after previous splenectomy
Owner requests second opinion or advanced treatment options

The American Animal Hospital Association provides resources for referral to board-certified specialists (AAHA, www.aaha.org). The American College of Veterinary Internal Medicine offers a directory of veterinary oncologists (ACVIM, www.acvim.org).

Implementation Checklist for Veterinary Practices

Develop a standardized splenic mass protocol based on the three-tier risk stratification model
Create a record template that captures all required data points
Train staff on emergency stabilization protocols for acute hemoperitoneum
Establish relationships with blood product suppliers and referral specialists
Implement continuous electrocardiographic monitoring for postoperative arrhythmia detection
Schedule regular team discussions of splenic mass cases to identify improvement opportunities
Maintain a case log for outcome tracking and quality assurance
Provide owner education materials that explain the risk stratification approach and expected outcomes

This practical decision framework provides a structured, evidence-based approach to managing canine splenic masses. By implementing the three-tier risk stratification model, standardized record system, and clear escalation criteria, veterinary practitioners can improve diagnostic accuracy, surgical outcomes, and owner communication.

Practical Decision Framework for Splenic Mass Management: The Three-Tier Risk Stratification Model

Tier 1: Preoperative Risk Stratification

Low-Risk Category

Patients meeting all of the following criteria:

Incidental finding on abdominal palpation or imaging
No evidence of hemoperitoneum on ultrasound
Mass less than 5 cm in diameter
Well-defined, homogeneous echogenicity on ultrasound
Normal coagulation profile (prothrombin time, activated partial thromboplastin time, platelet count)
No evidence of metastatic disease on thoracic radiographs and abdominal ultrasound
Breed not predisposed to hemangiosarcoma (e.g., small breed dogs)

For low-risk patients, consider:

Elective scheduling of splenectomy with histopathology
Preoperative fine-needle aspiration for cytology (acknowledging limitations)
Owner education about the 30-40% probability of malignancy based on published data

Moderate-Risk Category

Patients meeting any of the following criteria:

Mass 5-10 cm in diameter
Heterogeneous echogenicity with cavitation or necrosis
Mild hemoperitoneum (small volume, patient hemodynamically stable)
Breed predisposition for hemangiosarcoma (German Shepherd Dog, Golden Retriever, Labrador Retriever)
Age over 10 years
Mild thrombocytopenia or prolonged coagulation times

For moderate-risk patients:

Schedule splenectomy within 24-48 hours
Cross-match and prepare blood products
Stage for metastatic disease before surgery
Discuss 50-70% probability of malignancy with owners

High-Risk Category

Patients meeting any of the following criteria:

Acute hemoperitoneum with hemodynamic instability
Mass greater than 10 cm in diameter
Evidence of rupture on ultrasound
Moderate to severe thrombocytopenia or coagulopathy
Suspicious metastatic lesions on staging
Previous history of splenic mass or hemangiosarcoma

For high-risk patients:

Emergency splenectomy after stabilization
Immediate cross-match and blood product availability
Cell salvage device if available
Discuss 70-90% probability of malignancy with owners
Prepare for potential intensive care unit admission postoperatively

Tier 2: Intraoperative Decision Algorithm

Step 1: Abdominal Exploration

Upon entering the abdomen, perform a systematic exploration:

Evaluate the splenic mass: size, location, vascular involvement, evidence of rupture
Inspect the liver: number, size, and appearance of nodules
Examine the mesenteric lymph nodes: enlargement, discoloration, texture
Assess the omentum and peritoneum for implants or discoloration
Evaluate the gastrointestinal tract for concurrent abnormalities

Document all findings in the medical record with specific measurements and descriptions.

Step 2: Splenic Pedicle Assessment

Determine the feasibility of complete resection:

Is the mass confined to the spleen with a definable pedicle?
Are the splenic artery and vein free of tumor invasion?
Is there adequate length for ligation proximal to the mass?

If the mass involves the splenic hilus or extends into the pancreatic tissue, consider:

Careful dissection to preserve pancreatic blood supply
Partial pancreatectomy if necessary
Consultation with a surgical specialist if available

Step 3: Liver Nodule Evaluation

When liver nodules are present, follow this protocol:

Count and measure all visible nodules
Note the color, texture, and distribution
Obtain wedge biopsy or core needle biopsy of at least one nodule
Submit separate samples for histopathology

A 2024 study found that ultrasonographic liver nodules in dogs with hemoperitoneum secondary to splenic tumor rupture are more often benign lesions (Ultrasonographic liver nodules are more often benign lesions in dogs with hemoperitoneum secondary to splenic tumor rupture, Journal of the American Veterinary Medical Association, 2024, PubMed). This finding supports proceeding with splenectomy even when liver nodules are present, as they may represent nodular hyperplasia instead of metastasis.

Step 4: Lymph Node Assessment

Evaluate and biopsy regional lymph nodes:

Splenic lymph node (located near the splenic hilus)
Hepatic lymph node
Mesenteric lymph nodes

Enlarged or discolored lymph nodes should be excised or biopsied for histopathology. Normal-appearing lymph nodes may still contain micrometastatic disease, particularly in hemangiosarcoma.

Step 5: Decision to Proceed or Abort

Consider aborting splenectomy only in the following circumstances:

Widespread peritoneal carcinomatosis
Extensive liver metastasis involving more than 50% of hepatic parenchyma
Uncontrollable hemorrhage from the splenic pedicle
Patient becomes hemodynamically unstable despite resuscitation

In most cases, splenectomy should proceed even with metastatic disease because:

Removal of the primary mass reduces the risk of fatal hemorrhage
Cytoreduction may improve response to adjuvant therapy
Histopathologic diagnosis guides treatment recommendations
Palliative benefit for patients with clinical signs

Tier 3: Postoperative Risk Stratification and Monitoring

The third tier uses histopathologic diagnosis to guide long-term monitoring and adjuvant therapy recommendations.

Benign Lesion Protocol

For dogs with histopathologic confirmation of:

Splenic hematoma
Nodular hyperplasia
Splenic infarction
Benign lymphoid hyperplasia

Recommended monitoring:

Routine wellness examinations every 6-12 months
No specific imaging or bloodwork required
Owner education about signs of recurrence (rare)
Return to normal activity within 2-4 weeks

Low-Grade Malignancy Protocol

For dogs with histopathologic confirmation of:

Low-grade hemangiosarcoma (low mitotic index, no vascular invasion)
Liposarcoma
Leiomyosarcoma
Fibrosarcoma

Recommended monitoring:

Physical examination every 2-3 months for the first year
Thoracic radiographs every 2-3 months
Abdominal ultrasound every 2-3 months
Complete blood count and chemistry panel every 2-3 months
Consider referral to veterinary oncologist for adjuvant therapy discussion

High-Grade Malignancy Protocol

For dogs with histopathologic confirmation of:

High-grade hemangiosarcoma (high mitotic index, vascular invasion, rupture)
Histiocytic sarcoma
Undifferentiated sarcoma
Metastatic disease at presentation

Recommended monitoring:

Physical examination every 1-2 months
Thoracic radiographs every 1-2 months
Abdominal ultrasound every 1-2 months
Complete blood count, chemistry panel, and coagulation profile every 1-2 months
Immediate referral to veterinary oncologist
Consider adjuvant chemotherapy (doxorubicin-based protocols)
Discuss clinical trial options

Record System for Splenic Mass Cases

A standardized record system ensures consistent documentation and facilitates outcome tracking. Implement the following minimum data set for every splenic mass case:

Preoperative Record

Patient signalment (breed, age, sex, weight)
Presenting complaint and duration
Physical examination findings (mucous membrane color, heart rate, pulse quality, abdominal palpation)
Ultrasound findings (mass size, echogenicity, cavitation, rupture, hemoperitoneum volume)
Staging results (thoracic radiographs, abdominal ultrasound, any additional imaging)
Laboratory values (packed cell volume, total solids, platelet count, prothrombin time, activated partial thromboplastin time)
Risk stratification category (low, moderate, high)
Owner discussion summary (risks, prognosis, cost estimates)

Intraoperative Record

Abdominal exploration findings (liver, lymph nodes, omentum, peritoneum)
Splenic mass description (size, location, vascular involvement, rupture)
Surgical technique (open vs. laparoscopic, ligation method)
Estimated blood loss
Blood products administered
Biopsy sites and sample identification
Complications encountered
Surgeon name and credentials

Postoperative Record

Histopathologic diagnosis (tumor type, grade, margins, vascular invasion, mitotic index)
Complication monitoring (arrhythmias, hemorrhage, pancreatitis)
Pain scores and analgesic requirements
Discharge date and medications
Follow-up schedule
Owner instructions

Long-Term Follow-Up Record

Recheck examination findings
Imaging results (thoracic radiographs, abdominal ultrasound)
Laboratory values
Adjuvant therapy details (chemotherapy protocol, doses, adverse effects)
Survival time and cause of death
Quality of life assessment

Common Failure Patterns in Splenic Mass Management

Diagnostic Failures

Overreliance on ultrasound alone: Ultrasound cannot reliably distinguish benign from malignant masses. A systematic review evaluated the validity of the double two-thirds rule for diagnosing hemangiosarcoma in dogs with nontraumatic hemoperitoneum due to a ruptured splenic mass (Evaluation of the validity of the double two-thirds rule for diagnosing hemangiosarcoma in dogs with nontraumatic hemoperitoneum due to a ruptured splenic mass: a systematic review, Journal of the American Veterinary Medical Association, 2022, PubMed). The review found variable accuracy, emphasizing that histopathology remains the gold standard.
Inadequate staging: Failing to obtain thoracic radiographs or abdominal ultrasound before surgery may miss metastatic disease and lead to inappropriate surgical decisions.
Cytology misinterpretation: Fine-needle aspiration of splenic masses has limited sensitivity for hemangiosarcoma. Blood contamination or sampling from necrotic areas can yield nondiagnostic or misleading results.

Surgical Failures

Incomplete hemostasis: Inadequate ligation of the splenic artery and vein can lead to life-threatening postoperative hemorrhage. Use of vascular clips or stapling devices may reduce this risk.
Pancreatic trauma: The splenic vasculature runs in close proximity to the pancreas. Aggressive dissection can cause pancreatitis, which complicates recovery and prolongs hospitalization.
Missed concurrent lesions: Failure to thoroughly explore the abdomen may result in missed metastatic lesions or concurrent splenic pathology.

Postoperative Management Failures

Inadequate arrhythmia monitoring: Ventricular arrhythmias are common after splenectomy, particularly in dogs with hemangiosarcoma. Continuous electrocardiographic monitoring for the first 24-48 hours is recommended.
Delayed recognition of hemorrhage: Postoperative hemorrhage from the splenic pedicle can be subtle. Serial packed cell volume measurements and blood pressure monitoring are essential.
Incomplete histopathologic evaluation: Submitting only a portion of the spleen or failing to provide adequate clinical history to the pathologist can result in incomplete or inaccurate diagnosis.

Welfare and Safety Context

Pain management: Dogs with splenic masses may experience chronic discomfort from mass effect or acute pain from rupture. Multimodal analgesia should be provided before, during, and after surgery.
Quality of life assessment: For dogs with malignant splenic masses, quality of life should be assessed regularly using validated tools. Owners should be counseled about expected outcomes and signs of deterioration.
Euthanasia considerations: When metastatic disease is extensive or the patient's quality of life is poor, euthanasia may be the most humane option. This decision should be made collaboratively with the owner and based on objective assessment.
Anesthetic safety: Dogs with hemoperitoneum and hemodynamic instability are at increased anesthetic risk. Preoperative stabilization, careful anesthetic monitoring, and availability of blood products are essential.

Professional Escalation Criteria

Refer to a veterinary oncologist or surgical specialist when:

The mass is large (greater than 10 cm) or involves the splenic hilus
Metastatic disease is suspected or confirmed on preoperative staging
The patient has concurrent coagulopathy that cannot be corrected
Laparoscopic splenectomy is desired but the surgeon lacks experience
Adjuvant chemotherapy is being considered for malignant lesions
The diagnosis is uncertain after initial workup and fine-needle aspiration
The patient has recurrent splenic masses after previous splenectomy
Owner requests second opinion or advanced treatment options

Implementation Checklist for Veterinary Practices

Develop a standardized splenic mass protocol based on the three-tier risk stratification model
Create a record template that captures all required data points
Train staff on emergency stabilization protocols for acute hemoperitoneum
Establish relationships with blood product suppliers and referral specialists
Implement continuous electrocardiographic monitoring for postoperative arrhythmia detection
Schedule regular team discussions of splenic mass cases to identify improvement opportunities
Maintain a case log for outcome tracking and quality assurance
Provide owner education materials that explain the risk stratification approach and expected outcomes

Frequently Asked Questions

What are the most common symptoms of a splenic mass in dogs?

Common symptoms include weakness, lethargy, anorexia, abdominal distension, pale mucous membranes, and acute collapse. Some dogs have no symptoms and the mass is found incidentally during abdominal palpation or imaging. Dogs with ruptured masses may present with acute hemoperitoneum and hemorrhagic shock.

How is a splenic mass diagnosed in dogs?

Diagnosis begins with abdominal ultrasound to characterize the mass and evaluate for hemoperitoneum. Fine-needle aspiration with cytology can provide a preliminary diagnosis, but histopathology after splenectomy is the gold standard. Staging with thoracic radiographs and abdominal ultrasound is performed to detect metastatic disease.

What is the difference between a splenic hematoma and hemangiosarcoma?

A splenic hematoma is a benign lesion consisting of organized blood clot within the splenic parenchyma. Hemangiosarcoma is a malignant tumor arising from vascular endothelium that is highly metastatic. They can appear similar on ultrasound and grossly, making histopathology essential for definitive diagnosis.

Is splenectomy always necessary for a splenic mass?

Splenectomy is recommended for most splenic masses because ultrasound and cytology cannot reliably distinguish benign from malignant lesions. Exceptions include small, well-defined masses in dogs with contraindications to surgery, where monitoring with serial ultrasound may be appropriate. The decision should be made on a case-by-case basis.

What is the prognosis for a dog with splenic hemangiosarcoma?

The prognosis for hemangiosarcoma is poor. Median survival time with surgery alone is 2-3 months. Adjuvant chemotherapy can extend survival to 6-9 months. Factors such as rupture at presentation, metastatic disease, and high mitotic index worsen the prognosis.

Can a dog live a normal life after splenectomy?

Yes, dogs can live a normal life after splenectomy. The spleen is not essential for survival, and other organs compensate for its functions. Dogs may have increased susceptibility to certain infections, but this is rare. Most dogs return to normal activity within 2-4 weeks after surgery.

What are the risks of splenectomy in dogs?

Risks include hemorrhage, cardiac arrhythmias, pancreatitis, infection, and anesthetic complications. Hemorrhage from the splenic pedicle is the most common intraoperative complication. Ventricular arrhythmias are common postoperatively and require monitoring and treatment.

How often should a dog be monitored after splenectomy for a malignant mass?

Dogs with malignant masses should be monitored every 1-3 months with physical examination, thoracic radiographs, and abdominal ultrasound. Bloodwork including complete blood count and chemistry panel should be performed at each visit. More frequent monitoring may be indicated for aggressive tumors.

Related Veterinary Guides

References and Further Reading

www.merckvetmanual.com
www.aaha.org
www.acvim.org
Merck Veterinary Manual. Merck Veterinary Manual.
Animal Health and Welfare. World Organisation for Animal Health.
Splenic mass diagnosis in dogs undergoing splenectomy according to breed size.. The Veterinary record, 2019.
Canine hemophagocytic histiocytic sarcoma: a proliferative disorder of CD11d+ macrophages.. Veterinary pathology, 2006.
Evaluation of the validity of the double two-thirds rule for diagnosing hemangiosarcoma in dogs with nontraumatic hemoperitoneum due to a ruptured splenic mass: a systematic review.. Journal of the American Veterinary Medical Association, 2022.
Splenic liposarcoma in dogs: 13 cases (2002-2012).. Journal of the American Veterinary Medical Association, 2015.
Ultrasonographic liver nodules are more often benign lesions in dogs with hemoperitoneum secondary to splenic tumor rupture.. Journal of the American Veterinary Medical Association, 2024.
Pre-operative Hemostatic Status in Dogs Undergoing Splenectomy for Splenic Masses.. Frontiers in veterinary science, 2022.
Outcome and prognostic factors for dogs with a histological diagnosis of splenic hematoma following splenectomy: 35 cases (2001-2013). Canadian Veterinary Journal, 2016.
Videolaparoscopic splenectomy with bipolar electrosurgery in dog with splenic mass. Acta Scientiae Veterinariae, 2015.
Canine fossa puncture in endoscopic sinus surgery: report of two cases. Brazilian Journal of Otorhinolaryngology, 2017.

This article is educational and is not a substitute for veterinary diagnosis or treatment. Contact a veterinarian for advice about an individual animal.